Novartis AG (TSX:NVS) Interest Received

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSX:NVS Novartis AG TSX:NVS
61 GF Score
Price C$27.60
GF Value C$25.50
Valuation Fairly Valued
! 2 Warning Signs
View Full Analysis

What is Novartis AG Interest Received?

Interest Received only applicable to companies reporting Cash Flow from Operations in direct method.

TSX:NVS
61GF Score
Novartis AG TSX:NVS
Interest Received is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Novartis AG (TSX:NVS) Overvalued in 2026?

Based on GuruFocus' analysis, Novartis AG stock appears to be overvalued. The current stock price of C$27.60 is trading 8.2% above its estimated GF Value™ of C$25.50. GuruFocus considers Novartis AG to be Fairly Valued.

Key valuation signals for TSX:NVS:

  • Interest Received:
  • GF Value™: C$25.50 vs. price of C$27.60 (8.2% above fair value)
  • GF Score™: 61/100 with 2 warning signs

No single metric tells the full story. See the TSX:NVS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Novartis AG Business Description

Address Lichtstrasse 35, Basel, CHE, 4056
Novartis is a Swiss global pharmaceutical company focused exclusively on innovative prescription medicines after spinning off its Sandoz generics business in 2023. Key therapeutic areas include cardiovascular disease, led by cholesterol-lowering Leqvio and heart-failure treatment Entresto; oncology, including breast cancer therapy Kisqali, radioligand therapy Pluvicto, and Scemblix for leukemia; immunology, with psoriasis and arthritis biologic Cosentyx; and neuroscience and rare diseases, including multiple sclerosis therapy Kesimpta and gene therapy Zolgensma. Novartis pioneered CAR-T cell therapy (Kymriah) and radioligand therapeutics, and maintains a large development pipeline across small molecules, biologics, gene and cell therapies. Headquartered in Basel, Switzerland, it sells medicines in most countries worldwide, with the United States its largest market. Its ADRs trade on the NYSE.
61GF Score

Get the complete analysis for TSX:NVS

Interest Received is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

C$27.60
Price
C$25.50
GF Value